BioSpace News Archive

OncoSec Medical Incorporated (the “Company” or “OncoSec”) (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced the Company is set to join the Russell Microcap ® Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US market o

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced its acquisition of Sugarmate, a popular mobile app for people with diabetes who use insulin. Sugarmate will become a wholly owned subsidiary of Tandem Diabetes Care, and will continue to be led by its founder, Josh Juster who has joined the Company as Vice President, Sugarmate. Financial terms of the acquisiti

Artax Biopharma, Inc., a biotechnology company focused on transforming autoimmune disease treatment, today announces the formation of their Scientific Advisory Board (SAB). The SAB is comprised of experts in Immuno

In a recent report by Transparency Market Research, the vendor landscape for global pulmonary arterial hypertension market is highly opportunistic.

The global hypertrophic cardiomyopathy therapeutics market has been anticipated in a report penned by Transparency Market Research to witness the dominance of industry players with a high sales rate.

BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces a change to the presentation time of the Company’s oral virtual presentation at the upcoming Next Gen Immuno-Oncology Congress.

Senzime AB announces that the company has initiated its Sales Ramp Up in the US to establish a direct sales force in key territories and that the company has signed distribution agreements for the Midwest and Northwest territories.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that it received early notification from the U.S. Food and Drug Administration that the company may proceed with initiating a Phase 3, randomized, double-blind, placebo-controlled trial of losmapimod in higher risk hospitalized adults with COVID-19.

Mateon was approved to use the platform following a review of the program as part of IBM Watson Health’s

Strategic Alliance Combines Yumanity’s Innovative Drug Discovery Platform with Merck’s Development and Commercialization Expertise in Neuroscience